MX2023005027A - Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados. - Google Patents

Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados.

Info

Publication number
MX2023005027A
MX2023005027A MX2023005027A MX2023005027A MX2023005027A MX 2023005027 A MX2023005027 A MX 2023005027A MX 2023005027 A MX2023005027 A MX 2023005027A MX 2023005027 A MX2023005027 A MX 2023005027A MX 2023005027 A MX2023005027 A MX 2023005027A
Authority
MX
Mexico
Prior art keywords
hair loss
deuterated
regimens
treatment
loss disorders
Prior art date
Application number
MX2023005027A
Other languages
English (en)
Spanish (es)
Inventor
James V Cassella
Original Assignee
Sun Pharmaceutical Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Inc filed Critical Sun Pharmaceutical Ind Inc
Publication of MX2023005027A publication Critical patent/MX2023005027A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023005027A 2020-10-28 2021-10-28 Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados. MX2023005027A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063106790P 2020-10-28 2020-10-28
US202163155637P 2021-03-02 2021-03-02
PCT/US2021/057123 WO2022094133A1 (en) 2020-10-28 2021-10-28 Regimens for the treatment of hair loss disorders with deuterated jak inhibitors

Publications (1)

Publication Number Publication Date
MX2023005027A true MX2023005027A (es) 2023-07-31

Family

ID=78725692

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005027A MX2023005027A (es) 2020-10-28 2021-10-28 Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados.

Country Status (14)

Country Link
US (1) US20230390292A1 (cg-RX-API-DMAC7.html)
EP (1) EP4236956A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023553253A (cg-RX-API-DMAC7.html)
KR (1) KR20230093504A (cg-RX-API-DMAC7.html)
AU (1) AU2021372512A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196551A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001201A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006808A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000085A (cg-RX-API-DMAC7.html)
IL (1) IL302401A (cg-RX-API-DMAC7.html)
JO (1) JOP20230090A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005027A (cg-RX-API-DMAC7.html)
PE (1) PE20231945A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022094133A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215520A1 (en) * 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) * 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CZ20033211A3 (cs) 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
EP3921318A1 (en) 2019-02-06 2021-12-15 Concert Pharmaceuticals Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2023018904A1 (en) * 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders

Also Published As

Publication number Publication date
AU2021372512A1 (en) 2023-06-22
JP2023553253A (ja) 2023-12-21
US20230390292A1 (en) 2023-12-07
PE20231945A1 (es) 2023-12-05
EP4236956A1 (en) 2023-09-06
CO2023006808A2 (es) 2023-09-08
CA3196551A1 (en) 2022-05-05
CL2023001201A1 (es) 2023-11-17
IL302401A (en) 2023-06-01
DOP2023000085A (es) 2023-07-31
WO2022094133A9 (en) 2023-05-19
WO2022094133A1 (en) 2022-05-05
JOP20230090A1 (ar) 2023-04-27
KR20230093504A (ko) 2023-06-27

Similar Documents

Publication Publication Date Title
MX2023002323A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2024000820A (es) Compuestos para la inhibicion de proteinas que contienen el dominio de pirina de la familia nlr 3 (nlrp3) y usos de estos.
MX2025012306A (es) Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano
MX2025003908A (es) Compuesto inhibidor de parg
CL2023001201A1 (es) Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados
ZA202206485B (en) Use of bi853520 in cancer treatment
MX2023010728A (es) Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor.
PH12022553501A1 (en) Alk2 inhibitors for the treatment of anemia
MX2024014317A (es) Tratamientos con nirogacestat
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
PH12023550780A1 (en) Line-1 inhibitors to treat disease
MX2024014121A (es) Metodos y composiciones para el tratamiento del exceso de glucocorticoides
MX2024006678A (es) Inhibidor de cdk4 para el tratamiento del cancer.
MX2024013641A (es) Regimenes de dosificacion para el tratamiento con inhibidores deuterados de jak
MX2022015146A (es) Tratamiento de la artritis reumatoide.
PH12021551975A1 (en) Use of vibegron to treat overactive bladder
MX2023002422A (es) Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson.
PH12021553098A1 (en) Treatment for synucleinopathies
MX2025001316A (es) Tratamiento de la urticaria con inhibidores de la cinasa de janus (jak)
WO2024026458A3 (en) Use of glycogen metabolism inhibitors for the treatment of cancer
JOP20240263A1 (ar) مثبطات ripk1 وطرق الاستخدام
EA201892360A1 (ru) Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak
MX2025010790A (es) Inhibidores de la vía cinasa janus 1 (jak1) para el tratamiento del asma
WO2024226493A3 (en) Treatment of memory loss with phosphodiesterase inhibitors
WO2025189114A8 (en) Cdk inhibitors and their use as pharmaceuticals